AbbVie, BI settle IP litigation surrounding BI's Cyltezo, a Humira biosimilar

AbbVie and Boehringer Ingelheim GmbH resolved all ongoing intellectual property litigation regarding BI's Cyltezo (adalimumab-adbm), a biosimilar to AbbVie's Humira (adalimumab). Cyltezo was FDA approved in August 2017 for chronic inflammatory diseases, including rheumatoid arthritis, psoriatic arthritis, psoriasis, Crohn's disease, axial spondyloarthritis, and ulcerative colitis. Per the settlement, BI can start selling Cyltezo in the US on July 1, 2023. In exchange for licensing BI its Humira patents, AbbVie will receive royalties on US sales once Cyltezo is launched. The settlement enables BI to be among the first companies to secure future patient access in the US to a Humira alternative.